Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

Esperion announced the nomination of ESP-2001, a highly specific allosteric ATP citrate lyase inhibitor, as a preclinical development candidate for the treatment of primary sclerosing cholangitis.